DPx Holdings B.V. acquires
Gallus BioPharmaceuticals
DPx Holdings B.V. is the privately held parent company of the Patheon
®
, DPx Fine Chemicals™ and Banner Life Sciences™ businesses. DPx00004R0
The two existing Gallus sites in St. Louis, Mo. and
Princeton, N.J. are the first Patheon biologic drug
substance sites in the U.S. and complement the two
existing sites in Groningen, the Netherlands and
Brisbane, Australia. Under the Patheon brand, these
sites will support the company's continued expertise
in biologics and support the needs of Patheon's
customers in this growing segment of the industry.
The Patheon pharma services business provides
commercial manufacturing, pharmaceutical product
development services for a full array of solid and
sterile dosage forms, and biologic and chemical drug
substance development and manufacturing. Patheon
is now a leading provider of process development as
well as clinical and commercial scale manufacturing
of mammalian cell culture derived products.
These enhanced capabilities further supports
OneSource
™
— the end-to-end development offering
that provides small-scale API and biologic drug
substance through to commercial manufacturing.
Visit www.patheon.com or www.gallusbiopharma.com for more information.
Expanding our biologics business with flexibility,
leading technology solutions and commercial operations.